Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,371
Recruiting: 3,969
Ph III recruiting: 536
Growth YoY: +9.5%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,407)

clinicaltrialsPublishedShowing 651–700 of 3,553 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05298176	Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors(COMBINATION)	completed	Phase 2	5	Amsterdam UMC, location VUmcOTHER	1	Mar 28, 2025	clinicaltrials
NCT02052778	A Study of TAS-120 in Patients With Advanced Solid Tumors	completed	Phase 1 / Phase 2	407	Taiho Oncology, Inc.INDUSTRY	13	Mar 27, 2025